Bret Wacker

1.8k total citations · 1 hit paper
10 papers, 1.4k citations indexed

About

Bret Wacker is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Bret Wacker has authored 10 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 2 papers in Genetics. Recurrent topics in Bret Wacker's work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (3 papers) and Peptidase Inhibition and Analysis (3 papers). Bret Wacker is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (3 papers) and Peptidase Inhibition and Analysis (3 papers). Bret Wacker collaborates with scholars based in United States, Netherlands and United Kingdom. Bret Wacker's co-authors include Lee Brettman, P. Santabárbara, Maher Albitar, John C. Byrd, R. Kanti, Vinay Jain, Michael J. Keating, Ian W. Flinn, Peter Hillmen and Jacques‐Louis Binet and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Bret Wacker

10 papers receiving 1.4k citations

Hit Papers

Therapeutic role of alemtuzumab (Campath-1H) in patients ... 2002 2026 2010 2018 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    2002 707 citations Michael J. Keating, Ian W. Flinn et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bret Wacker United States 8 744 640 580 435 370 10 1.4k
Celeste Bello United States 13 640 0.9× 808 1.3× 544 0.9× 247 0.6× 98 0.3× 63 1.3k
Bruno Cazin France 19 1.3k 1.7× 1.1k 1.8× 336 0.6× 662 1.5× 150 0.4× 47 1.8k
Mehrdad Mobasher United States 16 903 1.2× 672 1.1× 433 0.7× 386 0.9× 177 0.5× 39 1.4k
Kathryn Humphrey United Kingdom 16 1.0k 1.4× 920 1.4× 433 0.7× 369 0.8× 198 0.5× 52 1.4k
Ilaria Del Giudice Italy 24 1.5k 2.0× 1.3k 2.0× 408 0.7× 764 1.8× 162 0.4× 82 1.9k
P. M. Kluin Netherlands 21 431 0.6× 1.0k 1.6× 797 1.4× 314 0.7× 135 0.4× 40 1.8k
Gunnar Juliusson Sweden 17 651 0.9× 663 1.0× 402 0.7× 369 0.8× 105 0.3× 56 1.5k
Ben Kennedy United Kingdom 15 1.2k 1.7× 1.1k 1.7× 209 0.4× 778 1.8× 93 0.3× 26 1.5k
Loïc Ysebaert France 15 914 1.2× 783 1.2× 308 0.5× 445 1.0× 93 0.3× 57 1.4k
Cinzia Pellegrini Italy 20 294 0.4× 1.1k 1.7× 519 0.9× 317 0.7× 230 0.6× 85 1.4k

Countries citing papers authored by Bret Wacker

Since Specialization
Citations

This map shows the geographic impact of Bret Wacker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bret Wacker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bret Wacker more than expected).

Fields of papers citing papers by Bret Wacker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bret Wacker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bret Wacker. The network helps show where Bret Wacker may publish in the future.

Co-authorship network of co-authors of Bret Wacker

This figure shows the co-authorship network connecting the top 25 collaborators of Bret Wacker. A scholar is included among the top collaborators of Bret Wacker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bret Wacker. Bret Wacker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Richardson, Frank C., Geoffrey D. Young, Julie Wolf, et al.. (2012). The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.. PubMed. 32(2). 537–52. 40 indexed citations
2.
Mita, Alain C., K. Papadopoulos, Maja J.A. de Jonge, et al.. (2011). Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. British Journal of Cancer. 105(7). 938–944. 36 indexed citations
3.
Wolf, Jürgen, Frances A. Shepherd, Federico Cappuzzo, et al.. (2011). Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.. Journal of Clinical Oncology. 29(15_suppl). 7533–7533. 8 indexed citations
4.
Hirsch, Fred R., Fairooz F. Kabbinavar, Tim Eisen, et al.. (2011). A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 29(26). 3567–3573. 67 indexed citations
5.
Hirsch, Fred R., Rafał Dziadziuszko, Wilbur A. Franklin, et al.. (2009). Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit. Journal of Clinical Oncology. 27(15_suppl). 8026–8026. 9 indexed citations
6.
7.
Kabbinavar, Fairooz F., Helen J. Ross, Renato Martins, et al.. (2007). D2-03: Erlotinib (E) as a single agent or intercalated with carboplatin and paclitaxel (ECP) in an EGFR biomarker-selected, previously untreated NSCLC population. Journal of Thoracic Oncology. 2(8). S394–S394. 1 indexed citations
8.
9.
R., K., Carl E. Freter, R Mercier, et al.. (2002). Alemtuzumab in Previously Treated Chronic Lymphocytic Leukemia Patients Who Also Had Received Fludarabine. Journal of Clinical Oncology. 20(18). 3891–3897. 236 indexed citations
10.
Keating, Michael J., Ian W. Flinn, Vinay Jain, et al.. (2002). Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 99(10). 3554–3561. 707 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Celeste Bello Breakdown of academic impact, for papers by Bruno Cazin Breakdown of academic impact, for papers by Mehrdad Mobasher Breakdown of academic impact, for papers by Kathryn Humphrey Breakdown of academic impact, for papers by Ilaria Del Giudice Breakdown of academic impact, for papers by P. M. Kluin Breakdown of academic impact, for papers by Gunnar Juliusson Breakdown of academic impact, for papers by Ben Kennedy Breakdown of academic impact, for papers by Loïc Ysebaert Breakdown of academic impact, for papers by Cinzia Pellegrini
Rankless by CCL
2026